DE59912185D1 - Verwendung von hsp70 protein - Google Patents

Verwendung von hsp70 protein

Info

Publication number
DE59912185D1
DE59912185D1 DE59912185T DE59912185T DE59912185D1 DE 59912185 D1 DE59912185 D1 DE 59912185D1 DE 59912185 T DE59912185 T DE 59912185T DE 59912185 T DE59912185 T DE 59912185T DE 59912185 D1 DE59912185 D1 DE 59912185D1
Authority
DE
Germany
Prior art keywords
hsp70 protein
cells
medical
fragments
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59912185T
Other languages
English (en)
Inventor
Prof Dr Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26045050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE59912185(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19813760A external-priority patent/DE19813760A1/de
Application filed by Individual filed Critical Individual
Priority to DE59912185T priority Critical patent/DE59912185D1/de
Application granted granted Critical
Publication of DE59912185D1 publication Critical patent/DE59912185D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464476—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
DE59912185T 1998-03-27 1999-03-29 Verwendung von hsp70 protein Expired - Lifetime DE59912185D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59912185T DE59912185D1 (de) 1998-03-27 1999-03-29 Verwendung von hsp70 protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19813760A DE19813760A1 (de) 1998-03-27 1998-03-27 Neue Verwendung von Hsp70-Protein
EP9902056 1999-03-26
DE59912185T DE59912185D1 (de) 1998-03-27 1999-03-29 Verwendung von hsp70 protein
PCT/EP1999/002165 WO1999049881A2 (de) 1998-03-27 1999-03-29 Verwendung von hsp70 protein

Publications (1)

Publication Number Publication Date
DE59912185D1 true DE59912185D1 (de) 2005-07-21

Family

ID=26045050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59912185T Expired - Lifetime DE59912185D1 (de) 1998-03-27 1999-03-29 Verwendung von hsp70 protein

Country Status (8)

Country Link
US (1) US7396681B1 (de)
EP (1) EP1066050B2 (de)
JP (1) JP4832640B2 (de)
AT (1) ATE297750T1 (de)
CA (1) CA2325735C (de)
DE (1) DE59912185D1 (de)
ES (1) ES2246566T5 (de)
WO (1) WO1999049881A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
ATE430161T1 (de) 2000-09-13 2009-05-15 Multimmune Gmbh Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
IL164799A0 (en) * 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
PT1537204E (pt) * 2002-08-23 2010-05-05 Gabriele Multhoff Granzima b como um indutor da apoptose em células tumorais dependente de hsp70/péptidos hsp70
WO2004087208A1 (ja) * 2003-03-27 2004-10-14 Ttc Co., Ltd. 熱ショックタンパク質と磁性微粒子からなる悪性腫瘍の温熱治療剤
DE60335549D1 (de) * 2003-11-12 2011-02-10 Alfa Biogene Internat B V Gewinnung von Hitzeschockproteinen
EP2079833A1 (de) * 2006-11-14 2009-07-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Zusammensetzungen und verfahren für die immuntherapie
PL2142642T3 (pl) * 2007-03-27 2017-10-31 Ipd Therapeutics B V Sposoby i środki do proliferacji komórek macierzystych oraz następczego wytwarzania i ekspansji komórek progenitorowych, jak również wytwarzania komórek efektorowych jako leków klinicznych
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
EP2454361A1 (de) * 2009-07-15 2012-05-23 Genome Research Limited Zellen, zusammensetzungen und verfahren
EP2580232A1 (de) * 2010-06-08 2013-04-17 National University of Ireland, Galway Manipulation von hsp70- und ire1alpha-proteininteraktionen
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
WO2013103792A2 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70)
PT3193840T (pt) 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
KR102254140B1 (ko) 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
EP4247792A1 (de) 2020-11-19 2023-09-27 Zevra Denmark A/S Verfahren zur herstellung von arimoclomolcitrat und zwischenprodukten davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) † 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
CA2079813A1 (en) † 1990-04-06 1991-10-07 Paul A. Berberian Method of treatment with hsp70
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
JPH07505719A (ja) † 1992-04-14 1995-06-22 デューク・ユニバーシティー ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法
DE4244715C2 (de) 1992-08-26 1995-06-14 Kuebler Gmbh Dr Verfahren zur Herstellung individuum-spezifischer, gegen Tumorantigene gerichtete monoklonale Antikörper
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
DE19647426C1 (de) * 1996-11-15 1998-06-25 Gsf Forschungszentrum Umwelt Human-Coloncarcinom-Zellinien mit stabiler HSP72-Expression
DE19813759C1 (de) * 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort

Also Published As

Publication number Publication date
EP1066050B2 (de) 2010-06-02
CA2325735C (en) 2013-06-04
ATE297750T1 (de) 2005-07-15
ES2246566T3 (es) 2006-02-16
WO1999049881A3 (de) 1999-12-23
JP4832640B2 (ja) 2011-12-07
EP1066050B1 (de) 2005-06-15
JP2002509892A (ja) 2002-04-02
CA2325735A1 (en) 1999-10-07
WO1999049881A2 (de) 1999-10-07
EP1066050A2 (de) 2001-01-10
ES2246566T5 (es) 2010-10-26
US7396681B1 (en) 2008-07-08

Similar Documents

Publication Publication Date Title
ATE297750T1 (de) Verwendung von hsp70 protein
HUP9800688A2 (hu) Gamma-ciklodextrin és retinol, ill. retinolszármazékok komplexei, eljárás ezek előállítására és ezeket tartalmazó kozmetikai és gyógyszerkészítmények
DK1149116T3 (da) Fremgangsmåde til fremstilling af multipelt tværbundne hyaluronsyrederivater
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
FI961886A0 (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
SE9704546D0 (sv) Novel compounds
CY1108770T1 (el) Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
WO1994012637A3 (en) Novel human amyloid protein precursor homologue and kunitz-type inhibitors
IL165988A0 (en) Process for the preparation of fibrinogen
BRPI0406037A (pt) Produto de carne ou análogo de carne contendo soja, e, método para preparar o mesmo
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
PT868522E (pt) Virus recombinante de poxvirus - virus da peritonite infecciosa felina, suas composicoes e metodos para a sua preparacao e utilizacao
TR200100637T2 (tr) Yeni doğal ürün türevleri
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings